Search | Clinical Trials Finder

Conditions: Head and Neck Cancer
Interventions: Xevinapant, Cisplatin, intensity-modulated radiation therapy (IMRT); Drug · Radiation
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 5
States / cities: Miami Beach, Florida • Detroit, Michigan • The Bronx, New York + 2 more

Conditions: Breast Cancer
Interventions: Single fraction of 7 Gy; Radiation
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Glioblastoma Multiforme
Interventions: CT-322, Temozolomide, Radiation Therapy; Drug · Procedure
Lead sponsor: Adnexus, A Bristol-Myers Squibb R&D Company; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 6
States / cities: Little Rock, Arkansas • Chicago, Illinois • Lexington, Kentucky + 3 more

Conditions: Prostate Cancer
Interventions: pembrolizumab, Low dose prostate radiation, Radical Prostatectomy; Drug · Radiation · Procedure
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Carcinoma, Squamous Cell, Carcinoma, Squamous Cell of Head and Neck
Interventions: Intraarterial Cetxuimab (Erbitux); Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Cutaneous Squamous Cell Carcinoma, Skin Cancer, Squamous Cell Carcinoma, Locally Advanced Squamous Cell Carcinoma, Locally Advanced Squamous Cell Carcinoma of the Skin, Locally Advanced Cutaneous Squamous Cell Carcinoma, Locally Advanced Skin Squamous Cell Carcinoma
Interventions: Cemiplimab, Radiotherapy; Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 13
States / cities: Aurora, Colorado • Tampa, Florida • Basking Ridge, New Jersey + 10 more

Conditions: Breast Cancer
Interventions: Hypofractionated radiotherapy, Pembrolizumab infusion, Blood and tissue sampling; Radiation · Drug · Procedure
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prostate Adenocarcinoma
Interventions: CyberKnife, Androgen Deprivation Therapy (ADT), Intensity Modulated radiation therapy (IMRT); Radiation · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older · Male only
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Park Ridge, Illinois

Conditions: Neuroblastoma
Interventions: UltratraceTM Iobenguane I 131 Imaging, UltratraceTM Iobenguane I 131 Therapy; Drug
Lead sponsor: Molecular Insight Pharmaceuticals, Inc.; Industry
Eligibility: 1 Year to 30 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 8
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 5 more

Conditions: Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Soft Palate
Interventions: LI, Cyclophosphamide, Indomethacin, Zinc, Surgery, Cisplatin, Radiotherapy; Biological · Drug · Dietary Supplement + 2 more
Lead sponsor: CEL-SCI Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 928 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 5
States / cities: Springfield, Illinois • Detroit, Michigan • Cincinnati, Ohio + 2 more

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Childhood Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Ringed Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes
Interventions: iodine I 131 monoclonal antibody BC8, fludarabine phosphate, total-body irradiation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, cyclosporine, mycophenolate mofetil, laboratory biomarker analysis; Radiation · Drug · Procedure + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 16 Years to 50 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2019
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Glioblastoma, Newly Diagnosed Glioblastoma
Interventions: Optune, Gadolinium, Temozolomide, Stereotactic radiosurgery (SRS); Device · Drug · Radiation
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Stanford, California

Conditions: Head and Neck Cancer, Mucositis, Pain, Radiation Toxicity
Interventions: palifermin, cisplatin, placebo, neck dissection, radiation therapy; Biological · Drug · Other + 2 more
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 47
States / cities: Scottsdale, Arizona • Auburn, California • Burbank, California + 40 more

Conditions: HPV-Related Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of the Hypopharynx
Interventions: Cisplatin, Radiation therapy, Vorinostat; Drug · Radiation
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Adenocarcinoma of the Pancreas, Pancreas Cancer
Interventions: CCX872-B; Drug
Lead sponsor: Alan Katz; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Colorectal Cancer, Carcinoma, Neuroendocrine, Neoplasm Metastasis
Interventions: Yttrium 90 glass microspheres; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 5
States / cities: Chicago, Illinois • Baltimore, Maryland • Rochester, Minnesota + 2 more

Conditions: Head and Neck Cancer
Interventions: CUDC-101, Cisplatin, Radiation Therapy; Drug · Radiation
Lead sponsor: Curis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 7
States / cities: Stanford, California • Aurora, Colorado • Shreveport, Louisiana + 4 more

Conditions: Melanoma, Skin Cancer
Interventions: MART-1: 26-35(27L) Peptide, Montanide ISA 51 VG, gp100:154-162 Peptide, Radiation, Aldesleukin, Fludarabine, Cyclophosphamide, Anti-gp 100:154 TCR PBL, Anti-MART-1 F5 TCR PBL; Drug · Procedure · Genetic
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Ovarian Neoplasms, Colorectal Neoplasms, Melanoma, Small Cell Lung Cancer, Liposarcoma
Interventions: Ionizing radiation (IR) therapy, Ionizing radiation (IR); Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 19 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Head and Neck Cancer
Interventions: Pembrolizumab, Surgery, Radiation Therapy, Cisplatin; Drug · Procedure · Radiation
Lead sponsor: Trisha Wise-Draper; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 6
States / cities: Louisville, Kentucky • Ann Arbor, Michigan • Cincinnati, Ohio + 3 more

Conditions: Prostate Cancer
Interventions: Radiotherapy, Samarium 153; Radiation · Drug
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 29
States / cities: Phoenix, Arizona • Auburn, California • Cameron Park, California + 22 more

Conditions: Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia, Paroxysmal Nocturnal Hemoglobinuria
Interventions: Rituximab, Rabbit ATG, Cyclophosphamide, Fludarabine, Total Body Irradiation, Cell Infusion, Post-Transplant G-CSF, Tacrolimus, Mycophenolate Mofetil; Drug · Radiation · Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 0 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2036
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Prostate Cancer
Interventions: CyberKnife Boost; Radiation
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metastatic Breast Cancer
Interventions: Pembrolizumab, Palliative radiotherapy; Drug · Radiation
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)

Study of Preoperative Boost Radiotherapy

CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme

Trimodality Approach of Low Dose iOnizing Radiation With or Without Neoadjuvant Pembrolizumab and Prostatectomy for Men With Intermediate/High Risk Prostate Cancer (TALON)

Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck

A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer

BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy

CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer

N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma

Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma

Palifermin in Lessening Oral Mucositis in Patients Undergoing Radiation Therapy and Chemotherapy for Locally Advanced Head and Neck Cancer

Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC

Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or Without CCX872-B

TheraSphere for the Treatment of Liver Metastases

Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer

Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma

An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation

Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma

Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

Hypofractionated Stereotactic Body Radiation Therapy as a Boost to the Prostate

Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC